Uncover key drivers, emerging technologies, and competitive movements shaping the histone deacetylase (hdac) inhibitors market from 2026–2035 with trusted insights from The Business Research Company
What is the estimated market size of the Histone Deacetylase (HDAC) Inhibitors Market by the end of 2030?
The histone deacetylase (hdac) inhibitors market has demonstrated significant growth in recent years. It is anticipated to increase from $1.32 billion in 2025 to $1.42 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.5%. Historically, this expansion has been driven by increased oncology drug research efforts, an enhanced understanding of epigenetic mechanisms, the expansion of clinical trial programs, rising pharmaceutical R&D investments, and the availability of advanced molecular screening tools.
The market for histone deacetylase (hdac) inhibitors is projected to experience substantial expansion in the coming years. This market is set to reach $1.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Key drivers for this anticipated growth include the increasing uptake of personalized cancer treatments, increased investments in developing epigenetic drugs, the broadening of neurology-focused hdac research, a rising demand for targeted therapeutic approaches, and more regulatory green lights for new hdac inhibitors. Noteworthy trends expected during this period involve a heightened focus on targeted epigenetic therapies, the accelerated development of selective hdac inhibitors, an expanding application of combination oncology treatments, the enlargement of precision medicine drug pipelines, and a stronger emphasis on drug discovery guided by biomarkers.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
What Drivers Are Shaping Future Opportunities In The Histone Deacetylase (HDAC) Inhibitors Market?
The increasing occurrence of neurodegenerative conditions is anticipated to fuel the expansion of the histone deacetylase (HDAC) inhibitors market in the future. These disorders involve the gradual deterioration and loss of neurons in the brain and spinal cord, resulting in impairments in cognitive and motor functions. Examples include Alzheimer’s, which is identified by memory loss and a decline in cognitive abilities, attributed to the presence of amyloid plaques and tau tangles. The growing prevalence of neurodegenerative diseases stems from various factors like age, increased lifespan, genetic predispositions, and environmental influences. Histone deacetylase (HDAC) inhibitors are being investigated as potential therapeutic options for neurodegenerative conditions, given their capacity to regulate gene expression and offer neuroprotective benefits. For example, data from August 2024 by the Centers for Disease Control and Prevention, a US-based federal agency, indicates that approximately 6.7 million older adults in the United States currently have Alzheimer’s disease, with projections showing this figure could climb to nearly 14 million by 2060. Consequently, the increasing incidence of neurodegenerative disorders is propelling the expansion of the histone deacetylase (HDAC) inhibitors market.
Which Segment Groups Are Influencing The Histone Deacetylase (HDAC) Inhibitors Market?
The histone deacetylase (hdac) inhibitors market covered in this report is segmented –
1) By Class: Class I HDACs, Class II HDACs, Class III HDACs
2) By Route Of Administration: Oral HDAC Inhibitors, Parenteral HDAC Inhibitors
3) By Application: Oncology, Neurology, Other Applications
4) By End User: Hospitals, Academic And Research Institutes, Pharmaceutical Companies, Other End Users
Subsegments:
1) By Class I HDACs: HDAC1, HDAC2, HDAC3, HDAC8
2) By Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, HDAC10
3) By Class III HDACs (Sirtuins): SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7
Which Trends Are Expected To Influence The Histone Deacetylase (HDAC) Inhibitors Market In The Upcoming Years?
Major companies in the histone deacetylase (HDAC) inhibitors market are concentrating on developing innovative solutions, such as HDAC inhibitors for cancer treatment, to enhance effectiveness and decrease adverse reactions. Histone deacetylase (HDAC) inhibitors are a category of pharmaceutical compounds utilized in cancer therapy. They function by hindering the activity of HDAC enzymes, which typically remove acetyl groups from histone proteins. This inhibition results in increased acetylation of histones, thereby altering chromatin structure and influencing gene expression. For instance, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company focused on creating first-in-class cancer therapies, was granted New HDAC Inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These advanced inhibitors are engineered to target specific HDAC enzymes implicated in cancer progression, aiming to disrupt abnormal gene expression patterns that contribute to tumor growth and metastasis. The patented compounds demonstrate enhanced potency and selectivity, minimizing off-target effects and improving safety profiles for patients undergoing treatment.
Who Are The Prominent Global Companies Shaping The Histone Deacetylase (HDAC) Inhibitors Market Landscape?
Major companies operating in the histone deacetylase (hdac) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Access The Complete Report For Deeper Market Insights:
Which Region Is Projected To Lead The Histone Deacetylase (HDAC) Inhibitors Market During The Forecast Period?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (hdac) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Histone Deacetylase (HDAC) Inhibitors Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase (HDAC) Inhibitors Market 2026, By The Business Research Company
Anti Infective Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market
Histone Deacetylase Inhibitors Market Report 2026
Kinase Inhibitors Market Report 2026
https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model